Acadia Healthcare Company Inc
$ 24.89
4.10%
11 Jun - close price
- Market Cap 2,198,931,000 USD
- Current Price $ 24.89
- High / Low $ 25.09 / 23.89
- Stock P/E N/A
- Book Value 21.58
- EPS -12.20
- Next Earning Report 2026-07-29
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.04 %
- ROE -0.41 %
- 52 Week High 30.20
- 52 Week Low 11.43
About
Acadia Healthcare Company, Inc. develops and operates inpatient psychiatric facilities, residential treatment centers, group homes, substance abuse facilities, and outpatient behavioral health facilities to serve the behavioral health and recovery needs of the communities in the United States. United States and Puerto Rico. The company is headquartered in Franklin, Tennessee.
Analyst Target Price
$28.86
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-29 | 2026-02-25 | 2025-11-05 | 2025-08-05 | 2025-05-12 | 2025-02-27 | 2024-10-30 | 2024-07-31 | 2024-05-01 | 2024-02-27 | 2023-11-02 | 2023-07-27 |
| Reported EPS | 0.37 | 0.07 | 0.72 | 0.83 | 0.4 | 0.64 | 0.91 | 0.91 | 0.84 | 0.85 | 0.91 | 0.92 |
| Estimated EPS | 0.26 | 0.1 | 0.66 | 0.71 | 0.36 | 0.7146 | 0.9 | 0.88 | 0.8 | 0.79 | 0.89 | 0.86 |
| Surprise | 0.11 | -0.03 | 0.06 | 0.12 | 0.04 | -0.0746 | 0.01 | 0.03 | 0.04 | 0.06 | 0.02 | 0.06 |
| Surprise Percentage | 42.3077% | -30% | 9.0909% | 16.9014% | 11.1111% | -10.4394% | 1.1111% | 3.4091% | 5% | 7.5949% | 2.2472% | 6.9767% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-07-29 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 0.37 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ACHC
2026-06-11 13:53:00
The first quarter earnings season revealed mixed results for hospital chains. While some companies like Universal Health Services outperformed revenue expectations, most saw their stock prices decline post-earnings, averaging a 16% drop. Acadia Healthcare, despite a revenue beat, was considered the weakest performer due to missing future EPS guidance, while Universal Health Services had the strongest Q1 among its peers.
2026-06-11 09:09:34
This article provides financial data specifically on the "Cash from investing activities" for Acadia Healthcare Company, Inc. (XETR:7RA). It notes that the market is closed and offers no specific values or changes in this snippet, serving more as a heading within a financial data platform.
2026-06-09 05:10:32
Acadia Healthcare (ACHC) stock rose 8.6% following an analyst upgrade from Raymond James and a strong Q1 2026 report with modestly higher 2026 earnings and EBITDA guidance. While the company aims to improve underperforming facilities and expand, investors should be aware of ongoing legal and regulatory investigations. The article suggests that despite optimism, the stock may still be overvalued, with some analysts forecasting a significant downside from current prices.
2026-06-08 16:09:12
This article provides financial information for Acadia Healthcare Company, Inc. (XETR:7RA), focusing specifically on its net debt. It presents the period, value, change, and percentage change for the company's net debt. The content is presented within the context of market data provided by ICE Data Services and FactSet.
2026-06-08 16:09:12
Jefferies reported on its meetings with various Healthcare Services companies, noting that healthcare service stocks saw an average gain of 0.5% last week while the S&P 500 declined. The firm upgraded Acadia Healthcare and maintained BrightSpring Health Services as a top pick, citing strong growth trajectories and strategic developments. Discussions with HCA Healthcare and Surgery Partners revealed insights into demand, payer mix challenges, and growth strategies within the hospital and surgery center sectors.
2026-06-08 02:40:18
Acadia Healthcare Company (ACHC) is gaining attention after a strong first quarter, leading to an analyst upgrade and increased 2026 guidance. Despite recent share price momentum, the company's valuation is split, with one narrative suggesting it's 105% overvalued at $11.94, while a DCF model indicates it's 70.8% undervalued with a fair value of $83.90. The discrepancy highlights the importance of evaluating both sentiment and cash flow analysis.
